← All updates
Observational study

Psychiatry · Endocrinology · 2 h ago

GLP-1RA initiation linked to improved metabolic markers in schizophrenia

A Danish nationwide register study used interrupted time-series analyses to assess metabolic markers after GLP-1 receptor agonist initiation in 3,042 people with schizophrenia. HbA1c, LDL and triglyceride levels declined after treatment began, both among those treated for diabetes and those treated for overweight.

Researchers used Danish nationwide registers to identify people with schizophrenia between 1996 and 2023 who initiated glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment. In this interrupted time-series analysis, they assessed changes in HbA1c, LDL and triglyceride levels after treatment initiation in 3,042 individuals. LDL and triglycerides were used as proxies for weight loss.

In practice

For people with schizophrenia who initiate GLP-1RA treatment, this Danish register analysis found reductions in HbA1c, LDL and triglycerides after treatment began, including among those treated for diabetes and overweight. The findings add real-world evidence in a population that may be underrepresented in trials, but the interrupted time-series observational design cannot establish that treatment caused the changes. The study reports biomarker outcomes; it does not establish effects on clinical events or identify comparative benefits of specific GLP-1RAs.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Sign in to rate this summary →

Source

The British Journal of Psychiatry: Metabolic biomarker levels before and after initiation of GLP-1 receptor agonist treatment among individuals with schizophrenia: interrupted time-series analysis ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.